Cemiplimab (anti-PD-1)

Catalog No.A2022        Batch: A202201

Print

Technical Data

CAS No. 1801342-60-8
Formulation PBS buffer. Contains no stabilizers or preservatives
Isotype Human IgG4
Source HEK293
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99.3%
Protein concentration 5 mg/ml
Endotoxin Level <1 EU/mg

Biological Activity

Description Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.
In vitro

In cell-based assays, REGN2810 reverses PD-1-dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells.[1]
In vivo

Cemiplimab (REGN2810) binds the humanized PD-1 receptor and inhibits growth of MC38 murine tumors in human PD-1 knock-in mice. As REGN2810 binds to cynomolgus monkey PD-1 with high affinity, pharmacokinetic and toxicologic assessment of REGN2810 is performed in cynomolgus monkeys. High doses of REGN2810 are well tolerated, without adverse immune-related effects.[1]

Protocol (Only for Reference)

Cell Assay:

  • Objective: T cell activation bioassays
    Cells: Jurkat/AP-1-Luc/hPD-1 cells, HEK293/hCD20 cells, HEK293/hCD20/hPD-L1 cells
    Concentrations: 0.1 pM-0.1 μM
    Incubation Time: 4-6 h
    Method: Antigenpresenting cell (APC)-like HEK293 cells are generated by lentiviral transduction of human CD20 and human PD-L1. T-cell receptor (TCR) activation is achieved by an antiCD3 x anti-CD20 bispecific antibody. To generate a dose response curve for anti-CD3 x anti-CD20, the bispecific molecule is serially diluted and tested with 50,000/well Jurkat/AP-1-Luc/hPD-1 and 10,000/well HEK293/hCD20 or HEK293/hCD20/hPD-L1 cells in a 96-well plate. Serially diluted REGN2810 is tested under similar conditions in the presence of a fixed concentration of anti-CD3 x anti-CD20 (100 pM). Plates are incubated at 37°C for 4-6 hours.
    Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

    Objective: T cell activation bioassays
    Cells: HEK293/hCD20/hPD-L1 cells, CD4+ T cells, HEK293/hCD20/hPD-L1 cells
    Concentrations: 0.1 pM-0.1 μM
    Incubation Time: 72 h
    Method: HEK293/hCD20/hPD-L1 cells are treated with 50 mg/mL mitomycin C for 30 minutes at 37°C to inhibit proliferation. Serially diluted REGN2810 is incubated with 50,000/well preactivated CD4+ T cells and 25,000/well of HEK293/hCD20/hPD-L1 cells in the presence of 2 nM anti-CD3 x anti-CD20 bispecific antibody in a 96-well plate for 72 hours.
    Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

    Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)
Animal Study:

  • Objective: MC38 mouse colon carcinoma
    Animal Models: adult human PD-1 knock-in mice
    Formulation: --
    Dosages: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/28265006

    Objective: pharmacokinetic (PK) study
    Animal Models: cynomolgus monkeys (Macaca fascicularis)
    Formulation: --
    Dosages: 1 mg/kg, 5 mg/kg, 15 mg/kg
    Administration: i.v.
    Reference: https://pubmed.ncbi.nlm.nih.gov/28265006

    Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

Selleck's Cemiplimab (anti-PD-1) has been cited by 1 publication

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors [ Life Sci Alliance, 2024, 7(3)e202302368] PubMed: 38176728

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.